# Flare Therapeutics

Source: https://onco.cc/companies/flare-therapeutics/  
OnCo record `flare-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Flare Therapeutics makes small-molecule drugs aimed at transcription factors, the proteins that switch genes on and off. Its two drugs in early trials are for advanced bladder (urothelial) cancer and for prostate cancer that has stopped responding to hormone treatment.

## Summary

Flare Therapeutics is a privately held Cambridge, Massachusetts company that says it works only on drugging transcription factors, with a chemistry and proteomics engine for finding ligands directly in cells. The company says its pipeline is initially focused on precision oncology. FX-909 is described as a first-in-class oral small-molecule inhibitor of PPARG, the master regulator of the luminal lineage, in a randomised Phase 1b study in PPARG-high locally advanced or metastatic urothelial cancer (NCT05929235, sponsored by Flare, active and not recruiting; one arm adds pembrolizumab). FX-111 is described as a degrader of the transcriptionally active, hormone-bound androgen receptor (AR ON) and is in a Phase 1 study in metastatic castration-resistant prostate cancer (NCT07719361, recruiting). The company also names a partnership with Roche. Third Rock Ventures lists Flare under its Cancer focus and gives 2021 as its year of investment.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Flare Therapeutics Inc.; FlareTx
- HQ: Cambridge, MA
- Type: biotech
- Website: https://www.flaretx.com/

## Notes

- Founding year not stated on the company site or the Third Rock entry (2021 is Third Rock's year of investment, not founding).
- Investors other than Third Rock are taken from the logo list on the company's About page (Investors tab); amounts and rounds were not read, so no funding rows.
- Neither trial is yet a trial record in OnCo; NCT05929235 and NCT07719361 were confirmed through the ClinicalTrials.gov v2 API with Flare as lead sponsor.
- The Roche partnership is named on the About page without terms.

## Sources

- Official website: https://www.flaretx.com/
- Pipeline page: https://www.flaretx.com/pipeline/
- FX-909 page: https://www.flaretx.com/fx-909/
- FX-111 page: https://www.flaretx.com/pipeline/fx-111/
- About and investors: https://www.flaretx.com/about/
- Third Rock Ventures portfolio entry: https://www.thirdrockventures.com/portfolio/flare-therapeutics

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/), [PPARG](https://onco.cc/targets/pparg/)
- drugs: [FX-111](https://onco.cc/drugs/fx-111/), [FX-909](https://onco.cc/drugs/fx-909/)
- companies: [Boxer Capital](https://onco.cc/companies/boxer-capital/), [Casdin Capital](https://onco.cc/companies/casdin-capital/), [Pfizer Ventures](https://onco.cc/companies/pfizer-ventures/), [Third Rock Ventures](https://onco.cc/companies/third-rock-ventures/)
- trials: [A Study in Patients With Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct07719361/), [A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma](https://onco.cc/trials/nct05929235/)

---
JSON: https://onco.cc/api/v1/entities/flare-therapeutics.json